Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update
May 07, 2020 16:05 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva
April 22, 2020 16:05 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development...
Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update
March 11, 2020 16:05 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 14, 2019 07:30 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer
October 30, 2019 16:05 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...
Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference
October 29, 2019 08:30 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Announces Multiple Presentations at ID Week 2019
October 03, 2019 16:01 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
September 30, 2019 01:00 ET
|
Entasis Therapeutics Holdings Inc.
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections...
Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 03, 2019 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
August 12, 2019 07:30 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...